Literature DB >> 6087315

Avian myeloblastosis virus and E26 virus oncogene products are nuclear proteins.

W J Boyle, M A Lampert, J S Lipsick, M A Baluda.   

Abstract

The defective acute leukemia viruses avian myeloblastosis virus (AMV) and E26 virus each contain an inserted cellular sequence related to the same highly conserved cellular gene, proto-amv. The oncogenes of these two retroviruses differ from this cellular proto-oncogene in gene structure, transcript structure, and gene product. The product of the AMV oncogene (myb) is a 48,000 Mr protein, p48myb, encoded by a transduced segment (amv) of proto-amv flanked by short helper-virus-derived terminal sequences. The E26 virus oncogene product is a 135,000 Mr protein, p135gag-amve-ets, encoded by significant portions of a viral structural gene (gag), sequences related to proto-amv (amve), and additional E26-specific sequences (ets) transduced from cellular proto-ets. Both p48myb and p135gag-amve-ets transforming proteins are located in the nucleus of cells transformed by these viruses. A protein of 110,000 Mr which is specifically immunoprecipitated by antisera to amv peptides and may be the product of the normal cellular gene (proto-amv) has been located in the cytoplasm of cells that express proto-amv mRNA.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6087315      PMCID: PMC345568          DOI: 10.1073/pnas.81.14.4265

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  Transcripts from the cellular homologs of retroviral oncogenes: distribution among chicken tissues.

Authors:  T J Gonda; D K Sheiness; J M Bishop
Journal:  Mol Cell Biol       Date:  1982-06       Impact factor: 4.272

2.  Three new types of viral oncogene of cellular origin specific for haematopoietic cell transformation.

Authors:  M Roussel; S Saule; C Lagrou; C Rommens; H Beug; T Graf; D Stehelin
Journal:  Nature       Date:  1979-10-11       Impact factor: 49.962

3.  Evidence that the src gene product of Rous sarcoma virus is membrane associated.

Authors:  J G Krueger; E Wang; A R Goldberg
Journal:  Virology       Date:  1980-02       Impact factor: 3.616

4.  Two cell lines from lymphomas of Marek's disease.

Authors:  Y Akiyama; S Kato
Journal:  Biken J       Date:  1974-09

5.  Preparation of syngeneic tumor regressor serum reactive with the unique determinants of the Abelson murine leukemia virus-encoded P120 protein at the cell surface.

Authors:  O N Witte; N Rosenberg; D Baltimore
Journal:  J Virol       Date:  1979-09       Impact factor: 5.103

6.  Localization of the ASV src gene product to the plasma membrane of transformed cells by electron microscopic immunocytochemistry.

Authors:  M C Willingham; G Jay; I Pastan
Journal:  Cell       Date:  1979-09       Impact factor: 41.582

7.  The transforming protein of Moloney murine sarcoma virus is a soluble cytoplasmic protein.

Authors:  J Papkoff; E A Nigg; T Hunter
Journal:  Cell       Date:  1983-05       Impact factor: 41.582

8.  Adhesion plaques of Rous sarcoma virus-transformed cells contain the src gene product.

Authors:  L R Rohrschneider
Journal:  Proc Natl Acad Sci U S A       Date:  1980-06       Impact factor: 11.205

9.  Association of the src gene product of Rous sarcoma virus with cytoskeletal structures of chicken embryo fibroblasts.

Authors:  J G Burr; G Dreyfuss; S Penman; J M Buchanan
Journal:  Proc Natl Acad Sci U S A       Date:  1980-06       Impact factor: 11.205

10.  Localization of the src gene product of the Harvey strain of MSV to plasma membrane of transformed cells by electron microscopic immunocytochemistry.

Authors:  M C Willingham; I Pastan; T Y Shih; E M Scolnick
Journal:  Cell       Date:  1980-04       Impact factor: 41.582

View more
  39 in total

1.  Subnuclear localization of the trans-activating protein of human T-cell leukemia virus type I.

Authors:  D J Slamon; W J Boyle; D E Keith; M F Press; D W Golde; L M Souza
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

2.  Definition of functional domains in P135gag-myb-ets and p48v-myb proteins required to maintain the response of neuroretina cells to basic fibroblast growth factor.

Authors:  C Garrido; D Leprince; J S Lipsick; D Stehelin; D Gospodarowicz; S Saule
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

3.  Transformation by v-myb correlates with trans-activation of gene expression.

Authors:  T Lane; C Ibanez; A Garcia; T Graf; J Lipsick
Journal:  Mol Cell Biol       Date:  1990-06       Impact factor: 4.272

4.  v-myb does not prevent the expression of c-myb in avian erythroblasts.

Authors:  J S Lipsick
Journal:  J Virol       Date:  1987-10       Impact factor: 5.103

5.  DNA-binding activity associated with the v-myb oncogene product is not sufficient for transformation.

Authors:  C E Ibanez; A Garcia; U Stober-Grässer; J S Lipsick
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

6.  Isolation of human cDNA clones of myb-related genes, A-myb and B-myb.

Authors:  N Nomura; M Takahashi; M Matsui; S Ishii; T Date; S Sasamoto; R Ishizaki
Journal:  Nucleic Acids Res       Date:  1988-12-09       Impact factor: 16.971

7.  Coordinate regulation of myelomonocytic phenotype by v-myb and v-myc.

Authors:  G Symonds; K H Klempnauer; M Snyder; G Moscovici; C Moscovici; J M Bishop
Journal:  Mol Cell Biol       Date:  1986-05       Impact factor: 4.272

8.  Multiple domains for the chicken cellular sequences homologous to the v-ets oncogene of the E26 retrovirus.

Authors:  A Gegonne; D Leprince; M Duterque-Coquillaud; B Vandenbunder; A Flourens; J Ghysdael; B Debuire; D Stehelin
Journal:  Mol Cell Biol       Date:  1987-02       Impact factor: 4.272

9.  trans activation of gene expression by v-myb.

Authors:  C E Ibanez; J S Lipsick
Journal:  Mol Cell Biol       Date:  1990-05       Impact factor: 4.272

10.  v-myb blocks granulocyte colony-stimulating factor-induced myeloid cell differentiation but not proliferation.

Authors:  G Patel; B Kreider; G Rovera; E P Reddy
Journal:  Mol Cell Biol       Date:  1993-04       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.